Matteo Ghisa

Dr. Matteo Ghisa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Pierfrancesco VisaggiPierfrancesco Visaggi
Pierfrancesco Visaggi
Brigida BarberioBrigida Barberio
Brigida Barberio
MGMatteo Ghisa
Matteo Ghisa
MRMentore Ribolsi
Mentore Ribolsi
VSVincenzo Savarino
Vincenzo Savarino
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
Esophageal cancer (EC) is the seventh most common cancer and the sixth cause of cancer death worldwide. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) account for up to 90% and 20% of all ECs, respectively. Clinical symptoms such as dysphagia, odynophagia, and bolus impaction occur late in the natural history of the disease, and the diagnosis is often delayed. The prognosis of ESCC and EAC is poor in advanced stages, being survival rates less than 20% at five years. However, when the diagnosis is achieved early, curative treatment is possible, and survival exceeds 80%. For these reasons, mass screening strategies for EC are highly desirable, and several options are currently under investigation. Blood biomarkers offer an inexpensive, non-invasive screening strategy for cancers, and novel technologies have allowed the identification of candidate markers for EC. The esophagus is easily accessible via endoscopy, and endoscopic imaging represents the gold standard for cancer surveillance. However, lesion recognition during endoscopic procedures is hampered by interobserver variability. To fill this gap, artificial intelligence (AI) has recently been explored and provided encouraging results. In this review, we provide a summary of currently available options to achieve early diagnosis of EC, focusing on blood biomarkers, advanced endoscopy, and AI.

9 September 2023 in Gastroenterology
Verified
Journal Article
Open access
IHIkuo Hirano
Ikuo Hirano
EDEvan S. Dellon
Evan S. Dellon
GFGary W. Falk
Gary W. Falk
NGNirmala P. Gonsalves
Nirmala P. Gonsalves
GFGlenn Furuta
Glenn Furuta
FKFei Li Kuang
Fei Li Kuang

1 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EMElisa Marabotto
Elisa Marabotto
GPGaia Pellegatta
Gaia Pellegatta
ASAfscin Djahandideh Sheijani
Afscin Djahandideh Sheijani
SZSebastiano Ziola
Sebastiano Ziola
PZPatrizia Zentilin
Patrizia Zentilin
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
In the last 30 years, we have witnessed a rapid increase in the incidence and prevalence of esophageal cancer in many countries around the word. However, despite advancements in diagnostic technologies, the early detection of this cancer is rare, and its prognosis remains poor, with only about 20% of these patients surviving for 5 years. The two major forms are the esophageal squamous cell carcinoma (ESCC), which is particularly frequent in the so-called Asian belt, and the esophageal adenocarcinoma (EAC), which prevails in Western populations. This review provides a summary of the epidemiological features and risk factors associated with these tumors. Moreover, a major focus is posed on reporting and highlighting the various preventing strategies proposed by the most important international scientific societies, particularly in high-risk populations, with the final aim of detecting these lesions as early as possible and therefore favoring their definite cure. Indeed, we have conducted analysis with attention to the current primary, secondary and tertiary prevention guidelines in both ESCC and EAC, attempting to emphasize unresolved research and clinical problems related to these topics in order to improve our diagnostic strategies and management.

16 May 2022 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PNPilar Navarro
Pilar Navarro
ELEmilio J Laserna-Mendieta
Emilio J Laserna-Mendieta
SCSergio Casabona-Francés
Sergio Casabona-Francés
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
MPMaría Teresa Pérez‐Fernández
María Teresa Pérez‐Fernández
Alfredo J. LucendoAlfredo J. Lucendo
Alfredo J. Lucendo
Background: Poor adherence to clinical practice guidelines for eosinophilic esophagitis (EoE) has been described and the diagnostic delay of the disease continues to be unacceptable in many settings.Objective: To analyze the impact of improved knowledge provided by the successive international clinical practice guidelines on reducing diagnostic delay and improving the diagnostic process for European patients with EoE.Methods: Cross‐sectional analysis of the EoE CONNECT registry based on clinical practice. Time periods defined by the publication dates of four major sets of guidelines over 10 years were considered. Patients were grouped per time period according to date of symptom onset.Results: Data from 1,132 patients was analyzed and median (IQR) diagnostic delay in the whole series was 2.1 (0.7‐6.2) years. This gradually decreased over time with subsequent release of new guidelines (p < 0.001), from 12.7 years up to 2007 to 0.7 years after 2017. The proportion of patients with stricturing of mixed phenotypes at the point of EoE diagnosis also decreased over time (41.3% vs. 16%; p < 0.001), as did EREFS scores. The fibrotic sub‐score decreased from a median (IQR) of 2 (1‐2) to 0 (0‐1) when patients whose symptoms started up to 2007 and after 2017 were compared (p < 0.001). In parallel, symptoms measured with the Dysphagia Symptoms Score reduced significantly when patients with symptoms starting before 2007 and after 2012 were compared. A reduction in the number of endoscopies patients underwent before the one that achieved an EoE diagnosis, and the use of allergy testing as part of the diagnostic workout of EoE, also reduced significantly over time (p = 0.010 and p < 0.001, respectively).Conclusion: The diagnostic work‐up of EoE patients improved substantially over time at the European sites contributing to EoE CONNECT, with a dramatic reduction in diagnostic delay.

30 June 2020 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
MGMatteo Ghisa
Matteo Ghisa
BBBrigida Barberio
Brigida Barberio
VSVincenzo Savarino
Vincenzo Savarino
EMElisa Marabotto
Elisa Marabotto
MRMentore Ribolsi
Mentore Ribolsi
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
Matteo Ghisa, Brigida Barberio, Vincenzo Savarino, Elisa Marabotto, Mentore Ribolsi, Giorgia Bodini, Fabiana Zingone, Marzio Frazzoni, and Edoardo Savarino. J Neurogastroenterol Motil 2020;26:311-21. https://doi.org/10.5056/jnm20046

12 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Pierfrancesco VisaggiPierfrancesco Visaggi
Pierfrancesco Visaggi
LMLucia Mariani
Lucia Mariani
VPVeronica Pardi
Veronica Pardi
EREmma Maria Rosi
Emma Maria Rosi
CPCamilla Pugno
Camilla Pugno
Nicola de BortoliNicola de Bortoli
Nicola de Bortoli
Eosinophilic esophagitis (EoE) is a unique form of non-immunoglobulin E-mediated food allergy, restricted to the esophagus, characterized by esophageal eosinophil-predominant inflammation and dysfunction. The diagnosis requires an esophago-gastroduodenoscopy with esophageal biopsies demonstrating active eosinophilic inflammation with 15 or more eosinophils/high-power field, following the exclusion of alternative causes of eosinophilia. Food allergens trigger the disease, withdairy/milk, wheat/gluten, egg, soy/legumes, and seafood the most common. Therapeutic strategies comprise dietary restrictions, proton pump inhibitors, topical corticosteroids, biologic agents, and esophageal dilation when strictures are present. However, avoidance of trigger foods remains the only option targeting the cause, and not the effect, of the disease. Because EoE relapses when treatment is withdrawn, dietary therapy offers a long-term, drug-free alternative to patients who wish to remain off drugs and still be in remission. There are currently multiple dietary management strategies to choose from, each having its specific efficacy, advantages, and disadvantages that both clinicians and patients should acknowledge. In addition, dietary regimens should be tailored around each individual patient to increase the chance of tolerability and long-term adherence. In general, liquid elemental diets devoid of antigens and elimination diets restricting causative foods are valuable options. Designing diets on the basis of food allergy skin tests results is not reliable and should be avoided. This review summarizes the most recent knowledge regarding the clinical use of dietary measures in EoE. We discussed endpoints, rationale, advantages and disadvantages, and tailoring of diets, as well as currently available dietary regimens for EoE.